# GLP-1/GIP Drugs & HRT in Midlife: What the New Data Suggests for Women's Health

Page: https://stenobird.com/podcast/menopause-mastery-4896737/glp-1-gip-drugs-hrt-in-midlife-what-the-new-data-suggests-for-women-s-health
Text version: https://stenobird.com/podcast/menopause-mastery-4896737/glp-1-gip-drugs-hrt-in-midlife-what-the-new-data-suggests-for-women-s-health.md
Podcast: [Menopause Mastery](https://stenobird.com/podcast/menopause-mastery-4896737)
Published: 2026-04-08T12:00:00+00:00
Episode link: https://thisfunctionallife.libsyn.com/glp-1gip-drugs-hrt-in-midlife-what-the-new-data-suggests-for-womens-health
Audio file: https://traffic.libsyn.com/secure/thisfunctionallife/EP_273_GLP_Drugs_audio.mp3?dest-id=3177122
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/menopause-mastery-4896737/episodes/glp-1-gip-drugs-hrt-in-midlife-what-the-new-data-suggests-for-women-s-health
Duration seconds: 1865

## Resource

GLP-1/GIP Drugs & HRT in Midlife: What the New Data Suggests for Women's Health | The Menopause Master Show | Episode 273 🩺 Rethinking GLP-1/GIP Drugs: A New Perspective on the Impact During Perimenopause and Menopause 🌱 Welcome to Menopause Mastery! In this episode, Dr. Betty Murray revisits prior criticism of GLP-1/GIP drugs (semaglutide, tirzepatide). She clarifies that the concern was poor prescribing and inadequate nutrition guidance, then reviews emerging data for midlife women in perimenopause/menopause. She explains how declining estrogen, progesterone, and testosterone shift fat distribution to the abdomen, worsen insulin resistance and cortisol, and change thyroid function, and note bioidentical hormone replacement therapy—especially transdermal estradiol—can improve glucose/fat metabolism and reduce visceral fat. They describe GLP-1 mechanisms, typical weight-loss ranges, and evidence women lose more than men, possibly due to overlapping estrogen and GLP pathways and potential synergy with HRT. A 2025 case report suggests GLP-1–slowed gastric emptying may temporarily reduce absorption of oral estrogen, bringing back symptoms, while transdermal estrogen may avoid this; they also raise concerns about possible birth-control absorption effects. Dr. Betty goes on to cover lean-mass loss risks on GLP drugs, sarcopenia concerns, potential bone effects of GIP, practical sequencing (start HRT then add GLP-1), microdosing/compounding considerations, and limits of current long-term trial data, emphasizing personalized care, protein intake, and resistance training. Have you ever wondered about GLP-1 drugs and their role in weight loss during menopause? This episode is for you if you are ready to unpack the mystery of GLP-1/GIP drugs. Before grabbing a prescription, dive…

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/menopause-mastery-4896737/episodes/glp-1-gip-drugs-hrt-in-midlife-what-the-new-data-suggests-for-women-s-health/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/menopause-mastery-4896737/glp-1-gip-drugs-hrt-in-midlife-what-the-new-data-suggests-for-women-s-health.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.